Final Results of NRG Oncology RTOG 0246: An Organ-Preserving Selective Resection Strategy in Esophageal Cancer Patients Treated with Definitive Chemoradiation

Stephen G. Swisher, Jennifer Moughan, Ritsuko U. Komaki, Jaffer A. Ajani, Tsung T. Wu, Wayne L. Hofstetter, Andre A. Konski, Christopher G. Willett

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Introduction The impact of selective surgical resection for patients with esophageal cancer treated with definitive chemoradiation has not been clearly evaluated long-term. Methods NRG (National Surgical Adjuvant Breast and Bowel Project, Radiation Therapy Oncology Group, Gynecologic Oncology Group) Oncology Radiation Therapy Oncology Group 0246 was a multi-institutional, single-arm, open-label, nonrandomized phase II study that enrolled 43 patients from September 2003 to March 2008 with clinical stage T1–4N0–1M0 squamous cell or adenocarcinoma of the esophagus or gastroesophageal junction from 19 sites. Patients received induction chemotherapy with fluorouracil (650 mg/m2/d), cisplatin (15 mg/m2/d), and paclitaxel (200 mg/m2/d) for two cycles followed by concurrent chemoradiation consisting of 50.4 Gy of radiation (1.8 Gy per fraction) and daily fluorouracil (300 mg/m2/d) with cisplatin (15 mg/m2/d) over the first 5 days. After definitive chemoradiation, patients were evaluated for residual disease. Selective esophagectomy was considered only for patients with residual disease after chemoradiation (clinical incomplete response) or recurrent disease on surveillance. Results This report looks at the long-term outcome of this selective surgical strategy. With a median follow-up of 8.1 years (minimum to maximum for 12 alive patients 7.2–9.8 years), the estimated 5- and 7-year survival rates are 36.6% (95% confidence interval [CI]: 22.3–51.0) and 31.7% (95% CI: 18.3–46.0). Clinical complete response was achieved in 15 patients (37%), with 5- and 7-yearr survival rates of 53.3% (95% CI: 26.3–74.4) and 46.7% (95% CI: 21.2–68.7). Esophageal resection was not required in 20 of 41 patients (49%) on this trial. Conclusions The long-term results of NRG Oncology Radiation Therapy Oncology Group 0246 demonstrate promising efficacy of a selective surgical resection strategy and suggest the need for larger randomized studies to further evaluate this organ-preserving approach.

Original languageEnglish (US)
Pages (from-to)368-374
Number of pages7
JournalJournal of Thoracic Oncology
Volume12
Issue number2
DOIs
StatePublished - Feb 1 2017

Fingerprint

Radiation Oncology
Neoplasms
Confidence Intervals
Radiotherapy
Fluorouracil
Cisplatin
Survival Rate
Radiation Dosage
Esophagogastric Junction
Induction Chemotherapy
Esophagectomy
Esophageal Neoplasms
Paclitaxel
Breast
Epithelial Cells

Keywords

  • Definitive chemoradiation
  • Esophageal cancer
  • Gastroesophageal junction
  • Selective esophagectomy

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine

Cite this

Final Results of NRG Oncology RTOG 0246 : An Organ-Preserving Selective Resection Strategy in Esophageal Cancer Patients Treated with Definitive Chemoradiation. / Swisher, Stephen G.; Moughan, Jennifer; Komaki, Ritsuko U.; Ajani, Jaffer A.; Wu, Tsung T.; Hofstetter, Wayne L.; Konski, Andre A.; Willett, Christopher G.

In: Journal of Thoracic Oncology, Vol. 12, No. 2, 01.02.2017, p. 368-374.

Research output: Contribution to journalArticle

Swisher, Stephen G. ; Moughan, Jennifer ; Komaki, Ritsuko U. ; Ajani, Jaffer A. ; Wu, Tsung T. ; Hofstetter, Wayne L. ; Konski, Andre A. ; Willett, Christopher G. / Final Results of NRG Oncology RTOG 0246 : An Organ-Preserving Selective Resection Strategy in Esophageal Cancer Patients Treated with Definitive Chemoradiation. In: Journal of Thoracic Oncology. 2017 ; Vol. 12, No. 2. pp. 368-374.
@article{305c9c5a2fce4c408b7c96e0953f6c4f,
title = "Final Results of NRG Oncology RTOG 0246: An Organ-Preserving Selective Resection Strategy in Esophageal Cancer Patients Treated with Definitive Chemoradiation",
abstract = "Introduction The impact of selective surgical resection for patients with esophageal cancer treated with definitive chemoradiation has not been clearly evaluated long-term. Methods NRG (National Surgical Adjuvant Breast and Bowel Project, Radiation Therapy Oncology Group, Gynecologic Oncology Group) Oncology Radiation Therapy Oncology Group 0246 was a multi-institutional, single-arm, open-label, nonrandomized phase II study that enrolled 43 patients from September 2003 to March 2008 with clinical stage T1–4N0–1M0 squamous cell or adenocarcinoma of the esophagus or gastroesophageal junction from 19 sites. Patients received induction chemotherapy with fluorouracil (650 mg/m2/d), cisplatin (15 mg/m2/d), and paclitaxel (200 mg/m2/d) for two cycles followed by concurrent chemoradiation consisting of 50.4 Gy of radiation (1.8 Gy per fraction) and daily fluorouracil (300 mg/m2/d) with cisplatin (15 mg/m2/d) over the first 5 days. After definitive chemoradiation, patients were evaluated for residual disease. Selective esophagectomy was considered only for patients with residual disease after chemoradiation (clinical incomplete response) or recurrent disease on surveillance. Results This report looks at the long-term outcome of this selective surgical strategy. With a median follow-up of 8.1 years (minimum to maximum for 12 alive patients 7.2–9.8 years), the estimated 5- and 7-year survival rates are 36.6{\%} (95{\%} confidence interval [CI]: 22.3–51.0) and 31.7{\%} (95{\%} CI: 18.3–46.0). Clinical complete response was achieved in 15 patients (37{\%}), with 5- and 7-yearr survival rates of 53.3{\%} (95{\%} CI: 26.3–74.4) and 46.7{\%} (95{\%} CI: 21.2–68.7). Esophageal resection was not required in 20 of 41 patients (49{\%}) on this trial. Conclusions The long-term results of NRG Oncology Radiation Therapy Oncology Group 0246 demonstrate promising efficacy of a selective surgical resection strategy and suggest the need for larger randomized studies to further evaluate this organ-preserving approach.",
keywords = "Definitive chemoradiation, Esophageal cancer, Gastroesophageal junction, Selective esophagectomy",
author = "Swisher, {Stephen G.} and Jennifer Moughan and Komaki, {Ritsuko U.} and Ajani, {Jaffer A.} and Wu, {Tsung T.} and Hofstetter, {Wayne L.} and Konski, {Andre A.} and Willett, {Christopher G.}",
year = "2017",
month = "2",
day = "1",
doi = "10.1016/j.jtho.2016.10.002",
language = "English (US)",
volume = "12",
pages = "368--374",
journal = "Journal of Thoracic Oncology",
issn = "1556-0864",
publisher = "International Association for the Study of Lung Cancer",
number = "2",

}

TY - JOUR

T1 - Final Results of NRG Oncology RTOG 0246

T2 - An Organ-Preserving Selective Resection Strategy in Esophageal Cancer Patients Treated with Definitive Chemoradiation

AU - Swisher, Stephen G.

AU - Moughan, Jennifer

AU - Komaki, Ritsuko U.

AU - Ajani, Jaffer A.

AU - Wu, Tsung T.

AU - Hofstetter, Wayne L.

AU - Konski, Andre A.

AU - Willett, Christopher G.

PY - 2017/2/1

Y1 - 2017/2/1

N2 - Introduction The impact of selective surgical resection for patients with esophageal cancer treated with definitive chemoradiation has not been clearly evaluated long-term. Methods NRG (National Surgical Adjuvant Breast and Bowel Project, Radiation Therapy Oncology Group, Gynecologic Oncology Group) Oncology Radiation Therapy Oncology Group 0246 was a multi-institutional, single-arm, open-label, nonrandomized phase II study that enrolled 43 patients from September 2003 to March 2008 with clinical stage T1–4N0–1M0 squamous cell or adenocarcinoma of the esophagus or gastroesophageal junction from 19 sites. Patients received induction chemotherapy with fluorouracil (650 mg/m2/d), cisplatin (15 mg/m2/d), and paclitaxel (200 mg/m2/d) for two cycles followed by concurrent chemoradiation consisting of 50.4 Gy of radiation (1.8 Gy per fraction) and daily fluorouracil (300 mg/m2/d) with cisplatin (15 mg/m2/d) over the first 5 days. After definitive chemoradiation, patients were evaluated for residual disease. Selective esophagectomy was considered only for patients with residual disease after chemoradiation (clinical incomplete response) or recurrent disease on surveillance. Results This report looks at the long-term outcome of this selective surgical strategy. With a median follow-up of 8.1 years (minimum to maximum for 12 alive patients 7.2–9.8 years), the estimated 5- and 7-year survival rates are 36.6% (95% confidence interval [CI]: 22.3–51.0) and 31.7% (95% CI: 18.3–46.0). Clinical complete response was achieved in 15 patients (37%), with 5- and 7-yearr survival rates of 53.3% (95% CI: 26.3–74.4) and 46.7% (95% CI: 21.2–68.7). Esophageal resection was not required in 20 of 41 patients (49%) on this trial. Conclusions The long-term results of NRG Oncology Radiation Therapy Oncology Group 0246 demonstrate promising efficacy of a selective surgical resection strategy and suggest the need for larger randomized studies to further evaluate this organ-preserving approach.

AB - Introduction The impact of selective surgical resection for patients with esophageal cancer treated with definitive chemoradiation has not been clearly evaluated long-term. Methods NRG (National Surgical Adjuvant Breast and Bowel Project, Radiation Therapy Oncology Group, Gynecologic Oncology Group) Oncology Radiation Therapy Oncology Group 0246 was a multi-institutional, single-arm, open-label, nonrandomized phase II study that enrolled 43 patients from September 2003 to March 2008 with clinical stage T1–4N0–1M0 squamous cell or adenocarcinoma of the esophagus or gastroesophageal junction from 19 sites. Patients received induction chemotherapy with fluorouracil (650 mg/m2/d), cisplatin (15 mg/m2/d), and paclitaxel (200 mg/m2/d) for two cycles followed by concurrent chemoradiation consisting of 50.4 Gy of radiation (1.8 Gy per fraction) and daily fluorouracil (300 mg/m2/d) with cisplatin (15 mg/m2/d) over the first 5 days. After definitive chemoradiation, patients were evaluated for residual disease. Selective esophagectomy was considered only for patients with residual disease after chemoradiation (clinical incomplete response) or recurrent disease on surveillance. Results This report looks at the long-term outcome of this selective surgical strategy. With a median follow-up of 8.1 years (minimum to maximum for 12 alive patients 7.2–9.8 years), the estimated 5- and 7-year survival rates are 36.6% (95% confidence interval [CI]: 22.3–51.0) and 31.7% (95% CI: 18.3–46.0). Clinical complete response was achieved in 15 patients (37%), with 5- and 7-yearr survival rates of 53.3% (95% CI: 26.3–74.4) and 46.7% (95% CI: 21.2–68.7). Esophageal resection was not required in 20 of 41 patients (49%) on this trial. Conclusions The long-term results of NRG Oncology Radiation Therapy Oncology Group 0246 demonstrate promising efficacy of a selective surgical resection strategy and suggest the need for larger randomized studies to further evaluate this organ-preserving approach.

KW - Definitive chemoradiation

KW - Esophageal cancer

KW - Gastroesophageal junction

KW - Selective esophagectomy

UR - http://www.scopus.com/inward/record.url?scp=85015319052&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85015319052&partnerID=8YFLogxK

U2 - 10.1016/j.jtho.2016.10.002

DO - 10.1016/j.jtho.2016.10.002

M3 - Article

C2 - 27729298

AN - SCOPUS:85015319052

VL - 12

SP - 368

EP - 374

JO - Journal of Thoracic Oncology

JF - Journal of Thoracic Oncology

SN - 1556-0864

IS - 2

ER -